A phase I/IIa study assessing single and multiple doses of hepatitis C virus (HCV) non-nucleoside polymerase inhibitor IDX375 in healthy and genotype 1 HCV-infected subjects

Start Date09 Jun 2010

Sponsor / Collaborator

Idenix Pharmaceuticals LLC

100 Clinical Results associated with IDX-375

100 Translational Medicine associated with IDX-375

100 Patents (Medical) associated with IDX-375

Literatures (Medical) associated with IDX-375

01 Jun 2017·Bioorganic & Medicinal Chemistry LettersQ4 · MEDICINE

Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor

Q4 · MEDICINE

Article

Author: Badaroux, Eric ; Pierra, Claire ; Paparin, Jean-Laurent ; Griffe, Ludovic ; Dukhan, David ; Onidi, Loredana ; Griffon, Jean-François ; Bot, Stéphanie ; Leroy, Frédéric ; Milhau, Julien ; Dousson, Cyril B ; Surleraux, Dominique ; Da Costa, Daniel ; Rosinosky, Elodie ; Convard, Thierry ; Giulia Loi, Anna ; Mascia, Valeria ; Rahali, Rachid ; Sais, Efisio ; Amador, Agnès ; LaColla, Massimiliano ; Seifer, Maria ; Liuzzi, Michel ; Caillet, Catherine ; McCarville, Joe ; Standring, David

Hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (RdRp) plays a central role in virus replication. NS5B has no functional equivalent in mammalian cells, and as a consequence is an attractive target for selective inhibition. This paper describes the discovery of a novel family of HCV NS5B non-nucleoside inhibitors inspired by the bioisosterism between sulfonamide and phosphonamide. Systematic structural optimization in this new series led to the identification of IDX375, a potent non-nucleoside inhibitor that is selective for genotypes 1a and 1b. The structure and binding domain of IDX375 were confirmed by X-ray co-crystalisation study.

01 Aug 2012·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

First-in-Human Study of the Pharmacokinetics and Antiviral Activity of IDX375, a Novel Nonnucleoside Hepatitis C Virus Polymerase Inhibitor

Q2 · MEDICINE

Article

Author: van Vliet, A. A. ; Molles, J. ; Pietropaolo, K. ; Temam, M. F. ; van de Wetering de Rooij, J. ; Zhou, X. J. ; de Bruijne, J. ; Mayers, D. ; Sullivan-Bólyai, J. Z. ; Chen, J. ; Reesink, H. W.

ABSTRACT IDX375 is a potent and selective palm-binding nonnucleoside inhibitor of the hepatitis C virus (HCV) genotype 1 polymerase. This first-in-human study evaluated the safety, tolerability, and pharmacokinetics of IDX375 in healthy volunteers, as well as its antiviral activity in HCV-infected patients. IDX375, as a choline salt, was administered for 1 day to 40 healthy male volunteers (25- to 200-mg IDX375-equivalent single ascending doses and a 200-mg twice-daily [BID] dose) and three patients chronically infected with HCV genotype 1 (200 mg BID only). IDX375 was well absorbed and well tolerated by all of the study participants. A single-day 200-mg BID dose resulted in exposure-related anti-HCV activity with maximal 0.5 to 1.1 log 10 reductions in plasma HCV RNA. These observations support further clinical investigations of IDX375.

100 Deals associated with IDX-375

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis C	Phase 2	US	Idenix Pharmaceuticals LLC	-
Hepatitis C	Phase 2	-	Merck Sharp & Dohme Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

IDX-375

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation